ArticleAnnals of medicine2026
Dose-response relationship between growth hormone treatment and the development of scoliosis in children with short stature.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe sought to investigate whether growth hormone (GH) treatment increases the risk of scoliosis in children with short stature and analyse a dose-response relationship.
methodsA retrospective cross-sectional and cohort study design was used. The cross-sectional study included 1160 children with short stature (355 and 805 in the GH-exposed and non-exposed groups, respectively). The scoliosis prevalence was compared. A total of 313 short stature children without scoliosis at baseline were enrolled in the cohort study (158 and 155, respectively, in the GH and non-GH groups). The median follow-up time was approximately 4.5 years. The relationship between risk factors and GH dose and the occurrence of scoliosis was evaluated with the outcome of new-onset scoliosis.
resultsThe incidence of scoliosis in the GH exposure group was significantly higher than that in the non-exposure group (5.40% vs. 2.40%, p=0.008). The risk of scoliosis in the GH group was 2.726 times higher than that in the non-GH group (HR=2.726, 95%CI: 1.326-5.605, p=0.006). The total GH dose was positively correlated with scoliosis risk, and there was a dose-response relationship between the total GH dose and the risk (HR=1.002, 95%CI: 1.001-1.003, p<0.001). A dose-response relationship was confirmed, with the predicted probability of scoliosis increasing continuously with cumulative GH dose.
conclusionsGH therapy is an independent risk factor for scoliosis in children with short stature, with a significant dose-response relationship. The cumulative GH dose can be used as a preliminary reference indicator for risk stratification and personalized monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.